Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 6/20 | 0.59 |
| ▸ | CCR6 | P51684 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15435062 | 0.90 | CXCR2 (0.55) | CXCR2CXCR1CCR6 | |
| SCHEMBL247709 | 0.88 | CXCR2 (0.63) | CXCR2CXCR1CCR6 | |
| SCHEMBL2297899 | 0.85 | CXCR2 (0.62) | CXCR2CXCR1CCR6 | |
| SCHEMBL2293257 | 0.84 | CCR6 (0.78) | CXCR2CCR6 | |
| SCHEMBL15435056 | 0.84 | CCR6 (0.78) | CXCR2CCR6 | |
| SCHEMBL2293252 | 0.84 | CCR6 (0.78) | CXCR2CCR6 | |
| SCHEMBL1579396 | 0.78 | GAA (0.54) | CXCR2CXCR1CCR6 | |
| SCHEMBL15435095 | 0.78 | CXCR2 (0.42) | CXCR2CXCR1CCR6 | |
| SCHEMBL2300135 | 0.78 | CXCR2 (0.42) | CXCR2CXCR1CCR6 | |
| SCHEMBL2296009 | 0.78 | CXCR2 (0.47) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2310359-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| WO-2010015613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885CXCR1 3/4885CCR6 57/4885 |
| US-20100029670-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CXCR1 2/4885CCR6 30/4885 |
| US-20140213594-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CXCR1 2/4885CCR6 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.